Morningstar Investor users sign in here.

Stocks

Winners and losers in healthcare

Quality companies hold a distinct advantage as they navigate the corona crisis but the sector at large remains resilient in the medium term, says Morningstar.  

Mentioned: Cochlear Ltd (COH), CSL Ltd (CSL), Ebos Group Ltd (EBO), Fisher & Paykel Healthcare Corp Ltd (FPH), Ramsay Health Care Ltd (RHC), Sigma Healthcare Ltd (SIG)


Healthcare stocks will prove their defensive worth during the coronavirus spread and Morningstar’s five-year outlook for the sector remains unchanged.

Companies exposed to elective surgery will be among the sufferers whereas providers of life-saving treatments—names such as biotech company CSL (ASX: CSL) and ventilator maker Fisher & Paykel (ASX: FPH)—will be more resilient.

And the direct pressures on the healthcare sector at large will play out in the next nine months.

They’re among the key findings in note by Morningstar healthcare sector analyst Nicolette Quinn, who sees an “opportune time” to buy into CSL.

Australian domestic pharma distributors, EBOS (ASX: EBO), API (ASX: API) and Sigma (ASX: SIG), will also benefit from increased volumes as people self-medicate to boost their immune systems, Quinn says.

She also sees upside for Blackmores (ASX: BKL), which boasts the largest market share in the vitamin and dietary supplement category.

“Beyond short-term covid-19 impacts, the sector is expected to uphold its reputation for defensiveness,” Quinn said on Monday.

Australian healthcare stocks ranked by discount/premium to fair value 

Healthcare stocks

Source: Morningstar; data as of 23 March 2020

Pharma distributors in box seat

Quinn says the nature of the crisis—a pandemic—means healthcare companies will behave differently.

Deferral of elective procedures is hurting certain device companies and hospitals, with Cochlear (ASX: COH) and Ramsay Healthcare (ASX: RHC) expected to be worst hit.

Pharma distributors on the other hand may gain as will CSL.

“Our top picks are the pharma distributors, EBOS, API and Sigma; vitamin company Blackmores; and CSL as we believe it is an opportune time to gain exposure to this high-quality company," Quinn says.

“We expect companies treating life-threatening illnesses, such as CSL and Fisher & Paykel, to be the most defensive, and the latter a clear direct beneficiary given its hospital respiratory devices business.

“In addition, those distributing pharmacy products stand to benefit from increased volumes, this includes the pharmaceutical distributors EBOS, API and Sigma."

The sector as a whole will slow but there will be growth, Quinn says.

“Currently we expect the direct covid-19 pressures on the healthcare system to play out in the next nine months. For the sector as a whole we forecast slowing, but positive, growth into fiscal 2021.

“Our five-year outlook for the sector is largely unchanged and we expect that should the current health crisis translate into a sustained economic downturn, the healthcare stocks should prove defensive.”

Healthcare stocks ranked from most positive to most negative short-term impacts from covid-19

Healthcare Stocks Ranked From Most Positive to Most Negative Short-Term Impacts From COVID-19

Source: Morningstar

The World Health Organisation says at least 20 covid-19 vaccines are in development in the global race for a cure.

Prem Icon
Prem Icon


© 2023 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.

More from Morningstar

Are miners attractive after the surge in gold prices?
Stocks

Are miners attractive after the surge in gold prices?

Gold prices are up around 50% in the last two months in anticipation that interest rate increases are coming to an end.
This five-star Aussie stock has a wide moat
Stocks

This five-star Aussie stock has a wide moat

Our analysts believe it can protect and grow its earnings for at least the next 20 years
Despite rally this A-REIT remains undervalued
Stocks

Despite rally this A-REIT remains undervalued

While attractive from a valuation standpoint we do not believe this A-REIT warrants a moat and is highly leveraged.
We advise waiting for a pullback before investing in the world's biggest company
Stocks

We advise waiting for a pullback before investing in the world's biggest company

We’ve raised our fair value estimate and sales forecast, but still see the stock as rich.
7 charts on the AI stock boom one year after ChatGPT’s launch
Stocks

7 charts on the AI stock boom one year after ChatGPT’s launch

These stocks and the key trends behind them are critical for understanding the AI investment landscape.
Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett
Stocks

Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett

Munger’s passing is a spiritual loss for the company.